Xencor, Inc.
Clinical trials sponsored by Xencor, Inc., explained in plain language.
Biotech engineering antibody therapeutics for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kidney cancer: experimental drug XmAb819 enters human trials Results expected Feb 2027 (estimated)
- First human trial of a new antibody drug begins Results expected May 2027 (estimated)
-
New antibody drug aims to tame ulcerative colitis
Disease control Recruiting nowThis study tests a new antibody drug called XmAb942 for moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. First, healthy volunteers will receive the drug to check safety. Then, about 270 people with ulcerative colitis will get either XmAb942 or a placeb…
Phase 1/2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New antibody drug enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo targets tough ovarian cancers
Disease control Recruiting nowThis early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for kidney cancer: experimental drug XmAb819 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug int…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New injection aims to tame rheumatoid arthritis
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called plamotamab in 68 adults with moderate to severe rheumatoid arthritis (RA) who haven't gotten enough relief from other treatments. The drug is given as a shot under the skin, and the main goal is to see if it's safe and …
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
First human trial of a new antibody drug begins
Knowledge-focused Recruiting nowThis study tests the safety and tolerability of a new drug called XmAb412, a monoclonal bispecific antibody, in healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The g…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC